GCITekcapital reveals the global medical oxygen concentrator and cylinder market
has revealed a new report in which Grand View Research estimates global medical sales of portable oxygen concentrators and cylinders.
Tekcapital owns 18.9% of the share capital of Belluscura, which is currently awaiting FDA clearance for its first portable oxygen concentrator, the X-PLO2RTM.
FDA clearance is currently anticipated in H1 2020.
Impact of COVID-19
Amongst other factors, the report examines the impact of new data from the COVID-19 pandemic on market demand and anticipates unit sales to grow from 405k units per year in 2019 to 581k units per year in 2026 for a total value of $1.4bn.
Reduced Lung Function
Additionally, a new study indicates recovered COVID-19 patients can be left with damaged lungs, which may require further oxygen treatment. Further investigations of the recovered COVID-19 patients must now be conducted to show whether they have developed pulmonary fibrosis - scarring in the lungs2.
According to Tekcapital director Robert Miller, M.D., "A portion of the patients who recover from COVID-19 may present residual lung damage, necessitating the use of supplemental oxygen."
References
1 https://drive.google.com/file/d/1s5Ou0UQWwjUfWAZ4TNcVMAtsBivvH9r5/view
2 https://www.dw.com/en/covid-19-recovered-patients-have-partially-reduced-lung-function/a-52859671
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.